

Pharmacy Request for Prior Approval – Juxtapid

Beneficiary Information				
1. Beneficiary Last Name:				
3. Beneficiary ID #:	4. Beneficiary Date of Birth:	5. Benefici	5. Beneficiary Gender:	
Prescriber Information				
	NPI #:			
Mailing address:			ZIP:	
7. Requester Contact Information:				
Name:	Phone #:	Fax #:		
Drug Information				
8. Drug Name:			r 30 Days:	
11. Length of Therapy:up to 30 days	60 days90 days12	20 days180 days365	daysOther:	
Clinical Information				
1. Has the beneficiary been diagnosed with homozygous familial hypercholesterolemia (HoFH)? Yes No				
2. Is the beneficiary enrolled in the Juxtapid REMS program? Yes No				
3. Is the beneficiary at least 18 years old or older? Yes No				
4. Is the beneficiary female? Yes No (if Yes, then answer 4a; if No, then move to question 5)				
4a. If female, has a negative pregnancy test been obtained? Yes No				
5. Has a measurement of the beneficiary's ALT, AST, alkaline phosphatase, and total bilirubin been obtained before initiating				
treatment? Yes No				
5a. ALT level: (U/L)				
5b. AST level: (U/L)				
5c. Alkaline phosphatase level: (U/L)				
5d. Bilirubin level: (mg/dL)				
6. For reauthorization:				
6a. During the first year, has the beneficiary received liver-related tests (ALT and AST, at a minimum) prior to each increase in				
dose or monthly, whichever occurs first? YesNo				
6b. After the first year, has the beneficiary received these tests at least every 3 months and before any increase in dose?				
Yes No 7. Failed two preferred drugs. List preferred drugs failed:				
7a. Allergic reaction:				
7b. Drug-to-drug interaction. Please describe reaction:				
8. Previous episode of an unacceptable side effect or therapeutic failure. Please provide clinical information:				
9. Clinical contraindication, co-morbidity, or unique patient circumstance as a contraindication to preferred drug(s). Please				
provide clinical information:				
11. Unique clinical indication supported by FDA approval or peer reviewed literature. Please explain and provide a general				
reference:				
12. Unacceptable clinical risk associated with therapeutic change. Please explain:				
Signature of Prescriber: Date:				

*Prescriber signature mandatory

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.